Palmoplantar pustulosis (PPP) is a chronic dermatosis that is often viewed as difficult to treat and manage. Many treatment modalities exist for PPP, starting with topical agents and moving to systemic medications in recalcitrant cases. We describe a patient with PPP who was initiated on ixekizumab following failure of several treatment modalities. After 3 months of using ixekizumab, the patient experienced significant improvement of symptoms with no reported side effects. This case demonstrates ixekizumab as an option in cases of recalcitrant PPP. To our knowledge, this is the first reported case of treatment success using ixekizumab monotherapy for PPP.
MarslandA.M.ChalmersR.J.HollisS.Leonardi-BeeJ.GriffithsC.E.. Interventions for chronic palmoplantar pustulosis.Cochrane Database Syst Rev.2006 Jan 25;(1): CD001433.
3.
PetteyA.A.BalkrishnanR.RappS.R.FleischerA.B.FeldmanS.R.. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice.J Am Acad Dermatol.2003 Aug; 49(2): 271–5. doi: http://dx.doi.org/10.1067/S0190–9622(03)01479–8.
4.
BissonnetteR.Suárez-fariñasM.LiX.Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris.PLoS ONE.2016; 11(5): e0155215.
5.
MurakamiM.HagforsenE.MorhennV.Ishida-yamamotoA.IizukaH.. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum.Exp Dermatol.2011; 20(10): 845–7.
6.
LeeE.ZareiM.LasennaC.VilladaG.RomanelliP.. Psoriasis Targeted Therapy: Characterization of Interleukin 17A Expression in Subtypes of Psoriasis.J Drugs Dermatol.2015; 14(10): 1133–6.
